WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches. HIV drug resistance has been rarely reported among PrEP users who tested HIV positive in randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy

These consolidated guidelines on HIV testing services (HTS) bring together existing and new guidance on HTS across different settings and populations. The World Health Organization (WHO) first released consolidated guidelines on HTS in 2015, in response to requests from Member States, national programme managers and health workers for support to achieve the United Nations (UN) 90–90–90 global HIV targets – and specifically the first target of diagnosing 90% of all people with HIV. In 2016, based on new evidence, WHO released a supplement to address important new HIV testing approaches – HIV self-testing (HIVST) and provider-assisted referral. Since the release of 2015 and 2016 HTS guidelines, new issues and more evidence have emerged. To address this, WHO has updated guidance on HIV testing services. In this guideline, WHO updates recommendation on HIVST and provides new recommendations on social network-based HIV testing approaches and western blotting (see box, next page). This guideline seeks to provide support to Member States, programme managers, health workers and other stakeholders seeking to achieve national and international goals to end the HIV epidemic as a public health threat by 2030. These guidelines also provide operational guidance on HTS demand creation and messaging; implementation considerations for priority populations; HIV testing strategies for diagnosis HIV; optimizing the use of dual HIV/syphilis rapid diagnostic tests; and considerations for strategic planning and rationalizing resources such as optimal time points for maternal retestin

Результаты исследования «Изучение распространенности коронавирусной инфекции COVID-19 среди инфицированных ВИЧ пациентов вРоссии ивлияния эпидемии коронавирусной инфекции COVID-19 на оказание медицинской помощипри ВИЧ-инфекции» This study shows the negative impact that the COVID-19 pandemic is having on access to HIV care in the Russian Federation and shows that people living with HIV in the country are more susceptible to COVID-19 but less likely to seek testing or treatment. More than a third of people living with HIV who were surveyed reported some impact on HIV services, including about 4% who reported that they had missed taking antiretroviral therapy because they could not get the medicine and nearly 9% who reported that they had missed taking medicine for tuberculosis prevention. However, the majority of respondents (about 70% of people living with HIV) did not experience problems obtaining antiretroviral therapy and about 22% reported that antiretroviral medicines were delivered to their home. More than 900 respondents from 68 regions of the Russian Federation, including people living with HIV and those who are not, were reached by the study

how to seize the moment to learn, leverage and build a new way forward for everyone’s health and rights This new report by UNAIDS examines how the experience of tackling HIV can help inform and guide effective, efficient, people-centred and sustainable COVID-19 responses

Applying the evidence of what works from HIV-related stigma and discrimination in six settings to the COVID-19 response This brief provide evidence-informed guidance to countries on the intersection of stigma related to HIV and COVID-19 in national responses

The aim of the operational framework is to ensure 1) accurate collection, handling, shipment and storage of specimens collected in countries implementing HIV drug resistance surveillance; and 2) the availability of quality-assured HIV genotyping laboratory services producing comparable and reliable results at the national, regional and global levels. This publication updates the WHO HIVResNet HIV drug resistance laboratory operational framework published in 2017 and reflects technical and strategic developments over the past three years

Уроки эпидемии ВИЧ-инфекции: эффективное реагирование силами сообщества Human rights in times of COVID-19

TB remains the top infectious killer in the world claiming close to 4000 lives a day. Millions of people continue to fall ill with TB- a preventable and curable disease each year. The Global TB Report 2020 provides a comprehensive and up-to-date assessment of the TB epidemic, and progress in the response, at global, regional and country levels in the context of global commitments and strategies. The report features data on disease trends and the response to the epidemic in 198 countries and territories. This includes trends in TB incidence and mortality, data on case detection and treatment results for TB, multidrug-resistant TB (MDR-TB), TB/HIV, TB prevention, universal health coverage as well as financing. Also included is an overview of pipelines for new TB diagnostics, drugs and vaccine

Accessed:10.03.2020

The COVID-19 pandemic has exposed the inadequacy of investments in public health, the persistence of profound economic and social inequalities and the fragility of many key global systems and approaches